Bruker makes laboratory analytical instruments used across life-science research, biopharma and applied markets; the company trades on Nasdaq with a market capitalization near $9.3 billion and sits in the Life Science Tools & CDMO theme.
Revenue has trended higher overall, rising from $742.8 million in CY2023Q3 to $838.5 million in CY2026Q2, and the model flags revenue acceleration. GAAP diluted EPS has been volatile and not accelerating, including negative GAAP EPS in CY2025Q3 and CY2026Q2, and several quarters with steep year-over-year EPS declines.
The combination of improving top-line momentum, a confirmed technical uptrend, and concentrated institutional ownership frames Bruker as a timely leader inside the life-science tools grouping: twelve-month excess return versus the S&P is 75.6%, and 557 institutions report holdings totaling about 95.85% of shares outstanding.
Why now
Revenue acceleration plus a constructive technical picture coincide with strong relative performance versus the S&P and near-universal institutional sponsorship, creating a clear leadership signal inside the Life Science Tools theme even though no fresh breakout setup is present.
The setup
Price closed at $61.39 on 2026-09-18, above the 50-day average ($58.20), the 9- and 21-day EMAs (58.52 and 57.82), and the 200-day average ($48.49); RSI is 57.66 and the stock sits about 4.9% above the 9-day EMA. Weinstein stage is 2 (continuation). Entry-readiness is labeled watch — the trend is established but there is no verified fresh breakout or 9/21 EMA add setup.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (13 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $2.12 (+16%) · FY'27E $2.39 (+13%) — 13 analysts
Risks
GAAP EPS has been inconsistent and occasionally negative, creating earnings volatility that could compress valuation if profitability does not normalize; revenue growth has not been monotonic—several quarters showed flat or slightly negative year-over-year revenue, so top-line momentum could stall; institutional ownership is very high (about 95.85%), which can reduce free float and amplify moves if large holders rotate out.
Framework fit
CANSLIM
4/7- CCurrent quarterly GAAP EPS growth ≥ 25%-920%✕
- AAnnual GAAP EPS growth ≥ 25%-120%✕
- NNew highs — within 15% of 52-week high-4.59%✓
- SSupply/demand — up-day volume leads0.86x✕
- LLeader — outperforming the S&P 500+67% 6m✓
- IInstitutional sponsorshipmodel score 9/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.